More reductions for Pfizer as it tacks on $2.5B in cost savings
Pfizer unveiled an additional $2.5 billion in planned cost savings through 2029 as it continues cutting costs and programs.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City. The company develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Company Info
Recent News
Pfizer unveiled an additional $2.5 billion in planned cost savings through 2029 as it continues cutting costs and programs.
Pfizer has dropped an obesity asset it acquired from Metsera along with a GIPR-targeting prospect as part of its portfolio pruning.
Pfizer CEO Albert Bourla defended the company's $7 billion bolt-on M&A strategy as peers rush to make larger acquisitions.
Pfizer is cutting an additional $2.5 billion across R&D and manufacturing as part of its ongoing restructuring.
Pfizer's Phase 3 win for Litfulo; Braveheart, Attovia eye IPOs of $275M, $182M. Reported by Endpoints News on 2026-07-30.
FDA expanded approval of Pfizer/Seagen's Padcev plus Merck's Keytruda combination to muscle-invasive bladder cancer (MIBC), intensifying competitive pressure on AstraZeneca's checkpoint inhibitor.
Pfizer, Innovent GLP-1 drugs clear China insurance hurdle. (Reuters Biopharma.)
Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.
Leadership Team
Chairman and Chief Executive Officer
Careers & Job Openings
No active job listings. Check back later.